Skip to main content
. Author manuscript; available in PMC: 2025 Apr 18.
Published in final edited form as: Cell Chem Biol. 2024 Mar 19;31(4):658–668.e14. doi: 10.1016/j.chembiol.2024.02.004

Figure 7. PROTACs inhibit Nef-dependent enhancement of HIV-1 replication in primary cells.

Figure 7.

A) Donor PBMCs were infected with wild-type HIV-1NL4-3 (DMSO control), a Nef-defective mutant (ΔNef), or wild-type virus in the presence of the Nef PROTACs shown at a final concentration of 1 μM. Input virus was 2,500 pg HIV p24 Gag per well. Replication was assayed by p24 Gag AlphaLISA 4 days later. Six independent determinations were assayed for each condition, and the highest and lowest p24 values were removed. Each bar indicates the mean ± SE of the remaining values with the individual data points shown. The dotted line indicates the mean value for the ΔNef control. Statistical significance was determined by Student’s t test between the DMSO control and ΔNef as well as each PROTAC treatment group; **, p < 0.01; ***, p < 0.001; ns, not significant. B) Viability of uninfected PBMCs was determined with each PROTAC at 1 μM after 4 days using the Cell Titer Blue assay (n = 6 wells/condition). The dotted line indicates 100% viability based on the DMSO control.